- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.
J Oncol Pract. 2017 Oct 05;:JOP2017027367
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Oncotarget. 2017 Aug 22;8(34):57528-57536
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
J Clin Oncol. 2017 Sep 11;:JCO2017729012
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Pharmacoeconomics. 2017 Aug 31;:
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung Cancer. 2017 Sep;111:23-29
Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study.
J Geriatr Oncol. 2017 Aug 19;:
Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.
J Clin Oncol. 2012 Dec;30(34_suppl):166
Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments.
J Clin Oncol. 2012 Dec;30(34_suppl):75
Cancer patients' and physicians' preferences for decision making regarding pharmacogenomic testing (PGT).
J Clin Oncol. 2012 Dec;30(34_suppl):13
Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision making.
J Clin Oncol. 2013 Nov;31(31_suppl):10
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group